Healy Urges Schools To Tighten Their Belts

National Institutes of Health director Bernadine Healy says that university administrators need to act more like their private-sector colleagues when it comes to dealing with the issue of indirect costs. If they don't, she warns, rising overhead rates will eat into the amount of new money available for academic research grants. "Every corporation in this country is trying to hold down its costs," Healy says, "and I think that university presidents need to do the same thing. Unfortunately, I

Written byJeffrey Mervis
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

"Every corporation in this country is trying to hold down its costs," Healy says, "and I think that university presidents need to do the same thing. Unfortunately, I don't see that happening."

Healy offered her comments outside the room where she opened last month's public hearing on a proposed draft report on managing research costs. The draft was put together by a working group of officials from NIH's parent agency, the Department of Health and Human Services. In her remarks to the academic officials in attendance, Healy said she would like to maintain the current proportion of NIH research funds, now at 31 percent, going to indirect costs. Current projections show that share rising to 33 percent by the end of the decade unless some belt-tightening takes place, she said.

In an interview, Healy said she believes that "some type of cap is a reasonable alternative." But she dispelled rumors ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies